Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Nascent Biotech Inc NBIO

Nascent Biotech Inc is a United States-based clinical stage biopharmaceutical company. It is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. It is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. They are also exploring the use of Pritumumab against other viruses.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (OTCQB:NBIO)

Fundamentals Snapshot (OTCQB:NBIO)

Opinion & Analysis (OTCQB:NBIO)

No current opinion is available.

Bullboard Posts (OTCQB:NBIO)

NBIO

Starting Phase 1 trial with Pritumumab (Prit.) for brain cancer. In partnership with university researchers and other clinicians as Prit....
ok2buy - September 1, 2020